Archives

Monthly Archive for: "June, 2018"

Home /

By FDM Digital

In News

Posted 25th June 2018

Mary Kerr CEO NeRRe Therapeutics and Managing Director KaNDY Therapeutics will be presenting a case study on the “Demerger of NT-814 to KaNDY Therapeutics, Business Model Innovation and Value Creation; 7TH LSX CEO FORUM , Wednesday 27th June 2018, CMS, Cannon Place, 78 Cannon St, London EC4N 6AF

By FDM Digital

In News

Posted 21st June 2018

KaNDy Therapeutics and NeRRe Therapeutics announce the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls

NeRRe Therapeutics is a UK based clinical-stage company developing a unique portfolio of neurokinin (NK) receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity.

Useful Links

Contact Us
About Us
Privacy Policy
Cookie Notice
Terms & Conditions
Clinical Trials Privacy Notice

Please fill out the form to get in touch with us.

I consent to NeRRe Therapeutics collecting my details through this form.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies Enabled Disabled

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies Enabled Disabled

Cookie Policy

More information about our Cookie Policy